<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210404</url>
  </required_header>
  <id_info>
    <org_study_id>A8121023</org_study_id>
    <nct_id>NCT01210404</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance</brief_title>
  <official_title>Open Label Single Sequence Study To Estimate The Effect Of Filibuvir (PF-00868554) On S-And R-Methadone In Subjects Receiving Chronic Methadone Treatment And To Evaluate The Pharmacokinetics Of Filibuvir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C
      infection. Given the likelihood of co administration of filibuvir and methadone, this study
      will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methadone plasma pharmacokinetic parameters, AUC24, Cmax</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Methadone plasma pharmacokinetic parameters, AUC24, Cmax</measure>
    <time_frame>day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Methadone plasma pharmacokinetic parameters Tmax and C24h</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methadone plasma pharmacokinetic parameters Tmax and C24h</measure>
    <time_frame>day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filibuvir plasma pharmacokinetic parameters: Auc 12, Cmax, and Tmax.</measure>
    <time_frame>day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filibuvir plasma pharmacokinetic parameters: Auc 12, Cmax, and Tmax.</measure>
    <time_frame>day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, including adverse events, vital signs, 12 lead ECG and lab safety assessments.</measure>
    <time_frame>days 0-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of methadone withdrawal as assessed by short Opiate Withdrawal Scale, Desires for Drug questionnaire and pupillary diameter measurement .</measure>
    <time_frame>days 0-12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filibuvir</intervention_name>
    <description>Filibuvir, 600mg bid administered along with methadone on days 2-11</description>
    <arm_group_label>1.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, without evidence of infection with HIV,HBV or HCV, who are on
             chronic methadone maintenance for at least three months and at a stable dose for at
             least 1 week prior to study start.

        Exclusion Criteria:

          -  Evidence of chronic diseases including HIV, HBV or HCV.

          -  Evidence of acute or chronic liver disease.

          -  Treatment with prescription or nonprescription drugs other than methadone within 7
             days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8121023&amp;StudyName=Drug%20Interaction%20Study%20Of%20Filibuvir%20With%20Methadone%20Among%20Subjects%20On%20Chronic%20Methadone%20Maintenance</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Drug interaction with methadone.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

